CureSHANK is a research advocacy organization focused on expediting life-changing therapies for Phelan-McDermid syndrome (PMS), a neurodevelopmental disorder caused by changes to the SHANK3 gene. We aim to bridge the gap between basic science and clinical trials through funding targeted research and organizing scientific meetings to connect stakeholders.
2019
84-2240648
$854 thousand
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
CureSHANK is dedicated to speeding up the research and development of treatments for those affected by Phelan-McDermid syndrome.
In 2023-2024, CureSHANK has allocated nearly $300,000 towards impactful PMS research grants.
This initiative fosters collaboration among various companies focused on SHANK3 therapeutics.
Overall Score
49
44
/100
Program Expense Ratio
88.35%
20
/20
Program Revenue Growth
0.00%
2
/20
Leverage Ratio
0
2
/20
Working Capital Ratio
3.888
18
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 487.3K | 100.00% |
Program Services | 0 | 0.00% |
Investment Income | 3 | 0.00% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 0 | 0.00% |
Total Revenue | 487.3K | 100.00% |
Med Research
Autism ResearchMed Research
Autism ResearchMed Research
Autism ResearchMed Research
Autism ResearchMed Research
Autism Research